Anil Gulati, MD, PhD is the Chairman and Chief Executive Officer at Pharmazz, Inc., Willowbrook, Illinois. He is Professor Emeritus at Midwestern University, the University of Illinois at Chicago, and is a consultant to Advocate Lutheran General Children's Hospital. He invented, developed, and obtained marketing authorization in India for a first-in-class resuscitative agent indicated for patients with massive blood loss. USFDA approved a phase III IND for hypovolemic shock and a phase II IND for ARDS. He leads the research, invention, and development of a novel drug to treat cerebral stroke in the late stages of clinical trials. In addition, he has discovered drugs potentially to treat Alzheimer's disease, hypoxic-ischemic encephalopathy, acute spinal cord injury, cardiac arrest, acute kidney injury, diabetic ketoacidosis, opioid tolerance, and dependence. Dr. Gulati has 54 issued patents. He is a recipient of the Outstanding Faculty Award 2017, Paul R Dawson Biotechnology Award 2014, and the distinguished Littlejohn Award 2014. Dr. Gulati is not only a United States Fulbright Scholar 2008-2009 but also a winner of the International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer of the United States Defense Medical Research and Development Program, Combat Casualty Care Research Program in 2016 and 2017. As the Professor and Associate Dean of Research, he promoted the medical research and faculty development of more than 50 faculty members. In addition, Dr. Gulati trained hundreds of medical residents and fellows to be research-oriented physicians and guided researches for more than 100 graduate students. He has ~300 peer-reviewed publications, 6,543 citations, an h-index of 45, an i10-index of 172. Dr. Gulati continues to forge ahead with discovering and developing new therapies for critically ill patients and his contributions to education and research.